---
document_datetime: 2025-12-02 05:38:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inrebic.html
document_name: inrebic.html
version: success
processing_time: 0.104411
conversion_datetime: 2025-12-28 05:35:43.340039
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Inrebic

[RSS](/en/individual-human-medicine.xml/67401)

##### Authorised

This medicine is authorised for use in the European Union

fedratinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Inrebic](#news-on)
- [More information on Inrebic](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Inrebic is a medicine used to treat adults with myelofibrosis (a rare form of blood cancer) who have enlarged spleen or other symptoms related to the disease.

Inrebic can be used in three types of the disease: primary myelofibrosis (also known as chronic idiopathic myelofibrosis, where the cause is unknown), post-polycythaemia vera myelofibrosis (where the disease is linked to an overproduction of red blood cells) and post-essential thrombocythaemia myelofibrosis (where the disease is linked to an overproduction of platelets, components that help the blood to clot).

Inrebic is used both in patients who have not been treated with medicines known as Janus kinase (JAK) inhibitors before and in those who have been treated with the JAK inhibitor ruxolitinib.

These diseases are rare, and Inrebic was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency's website ( [primary myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-794) : 1 October 2010; [post-polycythaemia vera myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-811) : 26 November 2010; [post-essential thrombocythaemia myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-810) : 26 November 2010).

Inrebic contains the active substance fedratinib.

Expand section

Collapse section

## How is Inrebic used?

The medicine can only be obtained with a prescription. Treatment with Inrebic should be started and supervised by doctors experienced in the use of cancer medicines.

Inrebic is available as capsules; the recommended dose is 400 mg once daily. Patients may also be given other medicines to stop them feeling sick or vomiting.

Treatment should continue for as long as the patient benefits from it. The doctor may reduce the dose, interrupt treatment or stop it altogether if the patient has certain side effects.

For more information about using Inrebic, see the package leaflet or contact your doctor or pharmacist.

## How does Inrebic work?

The active substance in Inrebic, fedratinib, works by blocking an enzyme known as JAK2, which is involved in the production and growth of blood cells. In myelofibrosis, there is too much JAK activity, leading to the abnormal production of blood cells. These blood cells migrate to organs, including the spleen, causing them to become enlarged. By blocking JAK2, Inrebic reduces the abnormal production of blood cells, thereby reducing symptoms of the disease.

## What benefits of Inrebic have been shown in studies?

In 2 main studies in patients with myelofibrosis, Inrebic was effective at reducing the size of patients' spleen.

In the first study, in patients with myelofibrosis who had not been treated with a JAK inhibitor before, 36% of patients (35 out of 97) given Inrebic had at least a 35% reduction in spleen size measured by a scan, compared with 1% (1 out of 96) of patients who received placebo. In this study, 40% of patients (36 out of 89) given Inrebic had at least 50% reduction in symptoms, measured using a myelofibrosis symptom rating scale, compared with 9% (7 out of 81) of patients who received placebo.

A second study involved patients with myelofibrosis who had already been treated with the JAK inhibitor ruxolitinib; for most of them, ruxolitinib treatment had not worked or could not be continued due to side effects, or the disease had come back. In this study, about 23% of patients (22 out of 97) receiving Inrebic 400 mg once daily had at least 35% reduction in spleen size.

## What are the risks associated with Inrebic?

The most common side effects with Inrebic (which may affect more than 1 in 10 people) are diarrhoea, nausea (feeling sick), vomiting, anaemia (low red blood cell counts) and thrombocytopenia (low blood platelet counts). The most common serious side effects (which may affect up to 1 in 10 people) are anaemia and diarrhoea.

Inrebic must not be used by pregnant women. For the full list of side effects and restrictions of Inrebic, see the package leaflet.

## Why is Inrebic authorised in the EU?

Inrebic has been shown to reduce spleen size in patients with myelofibrosis who had not been treated with JAK inhibitors before and in those who had previously been treated with ruxolitinib. Reduction in spleen size and associated symptoms is considered of major clinical relevance for patients with myelofibrosis. In terms of safety, side effects of Inrebic are considered manageable.

The European Medicines Agency therefore decided that Inrebic's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Inrebic?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inrebic have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Inrebic are continuously monitored. Side effects reported with Inrebic are carefully evaluated and any necessary action taken to protect patients.

## Other information about Inrebic

Inrebic received a marketing authorisation valid throughout the EU on 8 February 2021.

Inrebic : EPAR - Medicine overview

Reference Number: EMA/694589/2020

English (EN) (123.08 KB - PDF)

**First published:** 03/03/2021

[View](/en/documents/overview/inrebic-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-690)

български (BG) (146.67 KB - PDF)

**First published:**

03/03/2021

[View](/bg/documents/overview/inrebic-epar-medicine-overview_bg.pdf)

español (ES) (120.74 KB - PDF)

**First published:**

03/03/2021

[View](/es/documents/overview/inrebic-epar-medicine-overview_es.pdf)

čeština (CS) (145.75 KB - PDF)

**First published:**

03/03/2021

[View](/cs/documents/overview/inrebic-epar-medicine-overview_cs.pdf)

dansk (DA) (121.37 KB - PDF)

**First published:**

03/03/2021

[View](/da/documents/overview/inrebic-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.38 KB - PDF)

**First published:**

03/03/2021

[View](/de/documents/overview/inrebic-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.68 KB - PDF)

**First published:**

03/03/2021

[View](/et/documents/overview/inrebic-epar-medicine-overview_et.pdf)

ελληνικά (EL) (146.16 KB - PDF)

**First published:**

03/03/2021

[View](/el/documents/overview/inrebic-epar-medicine-overview_el.pdf)

français (FR) (121.8 KB - PDF)

**First published:**

03/03/2021

[View](/fr/documents/overview/inrebic-epar-medicine-overview_fr.pdf)

hrvatski (HR) (142.97 KB - PDF)

**First published:**

03/03/2021

[View](/hr/documents/overview/inrebic-epar-medicine-overview_hr.pdf)

italiano (IT) (120.07 KB - PDF)

**First published:**

03/03/2021

[View](/it/documents/overview/inrebic-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (150.98 KB - PDF)

**First published:**

03/03/2021

[View](/lv/documents/overview/inrebic-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.49 KB - PDF)

**First published:**

03/03/2021

[View](/lt/documents/overview/inrebic-epar-medicine-overview_lt.pdf)

magyar (HU) (143.75 KB - PDF)

**First published:**

03/03/2021

[View](/hu/documents/overview/inrebic-epar-medicine-overview_hu.pdf)

Malti (MT) (143.87 KB - PDF)

**First published:**

03/03/2021

[View](/mt/documents/overview/inrebic-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.8 KB - PDF)

**First published:**

03/03/2021

[View](/nl/documents/overview/inrebic-epar-medicine-overview_nl.pdf)

polski (PL) (145.33 KB - PDF)

**First published:**

03/03/2021

[View](/pl/documents/overview/inrebic-epar-medicine-overview_pl.pdf)

português (PT) (121.08 KB - PDF)

**First published:**

03/03/2021

[View](/pt/documents/overview/inrebic-epar-medicine-overview_pt.pdf)

română (RO) (140.21 KB - PDF)

**First published:**

03/03/2021

[View](/ro/documents/overview/inrebic-epar-medicine-overview_ro.pdf)

slovenčina (SK) (144.61 KB - PDF)

**First published:**

03/03/2021

[View](/sk/documents/overview/inrebic-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.77 KB - PDF)

**First published:**

03/03/2021

[View](/sl/documents/overview/inrebic-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.58 KB - PDF)

**First published:**

03/03/2021

[View](/fi/documents/overview/inrebic-epar-medicine-overview_fi.pdf)

svenska (SV) (118.93 KB - PDF)

**First published:**

03/03/2021

[View](/sv/documents/overview/inrebic-epar-medicine-overview_sv.pdf)

Inrebic : EPAR - Risk management plan

English (EN) (5.52 MB - PDF)

**First published:** 03/03/2021

**Last updated:** 05/03/2025

[View](/en/documents/rmp/inrebic-epar-risk-management-plan_en.pdf)

## Product information

Inrebic : EPAR - Product information

English (EN) (325.57 KB - PDF)

**First published:** 03/03/2021

**Last updated:** 23/07/2025

[View](/en/documents/product-information/inrebic-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-546)

български (BG) (406.27 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/bg/documents/product-information/inrebic-epar-product-information_bg.pdf)

español (ES) (328.88 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/es/documents/product-information/inrebic-epar-product-information_es.pdf)

čeština (CS) (424.07 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/cs/documents/product-information/inrebic-epar-product-information_cs.pdf)

dansk (DA) (329.4 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/da/documents/product-information/inrebic-epar-product-information_da.pdf)

Deutsch (DE) (348.79 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/de/documents/product-information/inrebic-epar-product-information_de.pdf)

eesti keel (ET) (324.18 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/et/documents/product-information/inrebic-epar-product-information_et.pdf)

ελληνικά (EL) (448.2 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/el/documents/product-information/inrebic-epar-product-information_el.pdf)

français (FR) (592.47 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

21/08/2025

[View](/fr/documents/product-information/inrebic-epar-product-information_fr.pdf)

hrvatski (HR) (414.57 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/hr/documents/product-information/inrebic-epar-product-information_hr.pdf)

íslenska (IS) (321.67 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/is/documents/product-information/inrebic-epar-product-information_is.pdf)

italiano (IT) (338 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/it/documents/product-information/inrebic-epar-product-information_it.pdf)

latviešu valoda (LV) (417.11 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/lv/documents/product-information/inrebic-epar-product-information_lv.pdf)

lietuvių kalba (LT) (417.7 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/lt/documents/product-information/inrebic-epar-product-information_lt.pdf)

magyar (HU) (385.58 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/hu/documents/product-information/inrebic-epar-product-information_hu.pdf)

Malti (MT) (432.35 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/mt/documents/product-information/inrebic-epar-product-information_mt.pdf)

Nederlands (NL) (332.23 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/nl/documents/product-information/inrebic-epar-product-information_nl.pdf)

norsk (NO) (321.88 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/no/documents/product-information/inrebic-epar-product-information_no.pdf)

polski (PL) (364.25 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/pl/documents/product-information/inrebic-epar-product-information_pl.pdf)

português (PT) (322.7 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/pt/documents/product-information/inrebic-epar-product-information_pt.pdf)

română (RO) (421.73 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/ro/documents/product-information/inrebic-epar-product-information_ro.pdf)

slovenčina (SK) (359.02 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/sk/documents/product-information/inrebic-epar-product-information_sk.pdf)

slovenščina (SL) (328.29 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/sl/documents/product-information/inrebic-epar-product-information_sl.pdf)

Suomi (FI) (331.77 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/fi/documents/product-information/inrebic-epar-product-information_fi.pdf)

svenska (SV) (323.68 KB - PDF)

**First published:**

03/03/2021

**Last updated:**

23/07/2025

[View](/sv/documents/product-information/inrebic-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0026 05/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Inrebic : EPAR - All authorised presentations

English (EN) (80.39 KB - PDF)

**First published:** 03/03/2021

[View](/en/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-37)

български (BG) (84.67 KB - PDF)

**First published:**

03/03/2021

[View](/bg/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_bg.pdf)

español (ES) (79.09 KB - PDF)

**First published:**

03/03/2021

[View](/es/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_es.pdf)

čeština (CS) (80.37 KB - PDF)

**First published:**

03/03/2021

[View](/cs/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (80.27 KB - PDF)

**First published:**

03/03/2021

[View](/da/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (80.73 KB - PDF)

**First published:**

03/03/2021

[View](/de/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (79.37 KB - PDF)

**First published:**

03/03/2021

[View](/et/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (81.11 KB - PDF)

**First published:**

03/03/2021

[View](/el/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_el.pdf)

français (FR) (79.29 KB - PDF)

**First published:**

03/03/2021

[View](/fr/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (79.28 KB - PDF)

**First published:**

03/03/2021

[View](/hr/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (80.96 KB - PDF)

**First published:**

03/03/2021

[View](/is/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_is.pdf)

italiano (IT) (78.7 KB - PDF)

**First published:**

03/03/2021

[View](/it/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (80.47 KB - PDF)

**First published:**

03/03/2021

[View](/lv/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (81.72 KB - PDF)

**First published:**

03/03/2021

[View](/lt/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (80.72 KB - PDF)

**First published:**

03/03/2021

[View](/hu/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (82.49 KB - PDF)

**First published:**

03/03/2021

[View](/mt/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (79.2 KB - PDF)

**First published:**

03/03/2021

[View](/nl/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (80.1 KB - PDF)

**First published:**

03/03/2021

[View](/no/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_no.pdf)

polski (PL) (81.2 KB - PDF)

**First published:**

03/03/2021

[View](/pl/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_pl.pdf)

português (PT) (79.43 KB - PDF)

**First published:**

03/03/2021

[View](/pt/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_pt.pdf)

română (RO) (79.79 KB - PDF)

**First published:**

03/03/2021

[View](/ro/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (82.83 KB - PDF)

**First published:**

03/03/2021

[View](/sk/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.65 KB - PDF)

**First published:**

03/03/2021

[View](/sl/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (77.59 KB - PDF)

**First published:**

03/03/2021

[View](/fi/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (79.94 KB - PDF)

**First published:**

03/03/2021

[View](/sv/documents/all-authorised-presentations/inrebic-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Inrebic Active substance fedratinib dihydrochloride monohydrate International non-proprietary name (INN) or common name fedratinib Therapeutic area (MeSH)

- Myeloproliferative Disorders
- Primary Myelofibrosis

Anatomical therapeutic chemical (ATC) code L01EJ02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

## Authorisation details

EMA product number EMEA/H/C/005026

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Bristol Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 10/12/2020 Marketing authorisation issued 08/02/2021 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Inrebic : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (174.3 KB - PDF)

**First published:** 06/09/2021

**Last updated:** 23/07/2025

[View](/en/documents/procedural-steps-after/inrebic-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Inrebic : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-608960

English (EN) (589.67 KB - PDF)

**First published:** 03/03/2021

[View](/en/documents/orphan-maintenance-report/inrebic-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Inrebic : EPAR - Public assessment report

Adopted

Reference Number: EMA/705612/2020

English (EN) (5.48 MB - PDF)

**First published:** 03/03/2021

**Last updated:** 09/06/2021

[View](/en/documents/assessment-report/inrebic-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Inrebic

Adopted

Reference Number: EMA/CHMP/636661/2020

English (EN) (112.76 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-inrebic_en.pdf)

#### News on Inrebic

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### More information on Inrebic

- [EU/3/10/794 - orphan designation for treatment of primary myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-794)
- [EU/3/10/811 - orphan designation for treatment of post-polycythaemia vera myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-811)
- [EU/3/10/810 - orphan designation for treatment of post-essential thrombocythaemia myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-810)

**This page was last updated on** 23/07/2025

## Share this page

[Back to top](#main-content)